Showing 5481-5490 of 5771 results for "".
- First Patient Treated in Multicenter Trial Examining Allotex TransForm Allogenic Refractive Lenticules for Treatment of Presbyopiahttps://modernod.com/news/first-patient-treated-in-multicenter-trial-examining-allotex-transform-allogenic-refractive-lenticules-for-treatment-of-presbyopia/2479889/Start-up ophthalmic device company Allotex announced the commencement of a European multicenter trial for its investigational TransForm allogenic refractive lenticules for the treatment of presbyopia. The treatment was performed on Thursday by Arthur Cummings, MB ChB, FCS(SA), MMed(Ophth)
- FDA to Review Eylea (Aflibercept) Injection for the Treatment of Diabetic Retinopathyhttps://modernod.com/news/fda-to-review-eylea-aflibercept-injection-for-the-treatment-of-diabetic-retinopathy/2479893/Regeneron Pharmaceuticals announced that the FDA has accepted for review the supplemental biologics license application of Eylea (aflibercept) injection for the treatment of diabetic retinopathy (DR). The target action date for the FDA decision is May 13, 2019. The supplemental biologics l
- Clearside Biomedical to Present Pivotal Phase 3 PEACHTREE Clinical Trial in Macular Edema Associated with Non-Infectious Uveitishttps://modernod.com/news/clearside-biomedical-to-present-pivotal-phase-3-peachtree-clinical-trial-in-macular-edema-associated-with-non-infectious-uveitis/2479896/Clearside Biomedical announced that data from PEACHTREE, its pivotal phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Rahul N. Khurana, MD, an investigator for PEACHTREE, Partner at Northern California Retina Vitreo
- SightMD, 24-Location Ophthalmology Group, and Chicago Pacific Founders Set Partnershiphttps://modernod.com/news/sightmd-24-location-ophthalmology-group-and-chicago-pacific-founders-set-partnership/2479899/SightMD, a provider of eyecare services through 24 locations, and Chicago Pacific Founders Fund LP, a health care investment fund, announced that they are entering into a partnership to expand SightMD’s patient-centric care model to patients, providers, and payers across the New York, New Jersey
- Alcon to Move Headquarters from Texas to Switzerland Following Proposed Spinoff From Novartishttps://modernod.com/news/alcon-to-move-headquarters-from-texas-to-switzerland-following-proposed-spinoff-from-novartis/2479901/Alcon announced plans to locate its future global headquarters in Geneva, Switzerland, following completion of its proposed spinoff from Novartis, which is expected to be completed in the first half of 2019. Alcon’s new global headquarters in Geneva will be the primary location for A
- Innovative “Pay It Forward” Training Program for Specialty Eye Surgeonshttps://modernod.com/news/innovative-pay-it-forward-training-program-for-specialty-eye-surgeons/2479905/The Refractive Surgery Alliance (RSA) announced the creation of a new and innovative training program for vision correction surgeons. The RSA program structure is unique and recognizes the expanding and rapidly evolving field refractive surgery. Instead of training surgeons under a single
- EyeSouth Expands into South Florida Through Affiliation with Florida Eye Microsurgical Institutehttps://modernod.com/news/eyesouth-expands-into-south-florida-through-affiliation-with-florida-eye-microsurgical-institute/2479907/EyeSouth Partners has announced that it has completed a strategic partnership with Florida Eye Microsurgical Institute and Boynton Beach ASC, expanding its presence into the South Florida region. EyeSouth is an eye care-focused physician services organization formed by Shore Capital Partners, a l
- Lenstec Completes Enrollment of FDA Trial for SBL-3 IOLhttps://modernod.com/news/lenstec-completes-enrollment-of-fda-trial-for-sbl-3-iol/2479919/Lenstec announced that it has completed enrollment of the FDA trial for the SBL-3 IOL. The Lenstec SBL-3 IOL (segmented bifocal lens) is a non-concentric asymmetric multifocal refractive IOL that provides patients with superior near, intermediate, and distance vision. It also improves contrast se
- Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Publishedhttps://modernod.com/news/scientific-data-for-novel-adeno-associated-virus-gene-therapy-in-rhodopsin-mediated-autosomal-dominant-retinitis-pigmentosa-published/2479920/Ophthotech announced that scientists at the University of Pennsylvania (Penn) and University of Florida published proof-of-concept study results on an adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-a
- Joseph Gordon Named US President of Bausch + Lombhttps://modernod.com/news/joseph-gordon-named-us-president-of-bausch-lomb/2479922/Bausch + Lomb announced that Joseph Gordon has been named US president, Bausch + Lomb. In this role, Mr. Gordon will oversee the fully integrated U.S. eye care business, inclusive of all four business units – Vision Care, Consumer Health, Surgical, and Pharmaceuticals. He will report direct